Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
Increases speed to market for drug developers working on nucleic acid therapeutics
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
ICMR will continue to track trends in HMPV circulation throughout the year
Subscribe To Our Newsletter & Stay Updated